PA5-64172

antibody from Invitrogen Antibodies

Targeting: SEZ6L2 FLJ90517, PSK-1

Immunohistochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-64172

Provider

Invitrogen Antibodies

Product name

SEZ6L2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: RGLISDAQSL YVELLSETPA NPLLLSLRFE AFEEDRCFAP FLAHGNVTTT DPEYRPGALA TFSCLPGYAL EPPGPPNAIE CV

Concentration

0.08 mg/mL

References

Submitted references

Seizure-related 6 homolog like 2 autoimmunity: Neurologic syndrome and antibody effects.

Landa J, Guasp M, Petit-Pedrol M, Martínez-Hernández E, Planagumà J, Saiz A, Ruiz-García R, García-Fernández L, Verschuuren J, Saunders-Pullman R, Ramirez-Gómez L, Geschwind MD, Dalmau J, Sabater L, Graus F
Neurology(R) neuroimmunology & neuroinflammation 2021 Jan;8(1)

Immunohistochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of SEZ6L2 in human cerebral cortex tissue shows strong cytoplasmic positivity in neuronal cells. Samples were probed using a SEZ6L2 Polyclonal Antibody (Product # PA5-64172).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of SEZ6L2 in human cerebral cortex and tonsil tissues using SEZ6L2 Polyclonal Antibody (Product # PA5-64172). Corresponding SEZ6L2 RNA-seq data are presented for the same tissues.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunohistochemical staining of SEZ6L2 in human tonsil using SEZ6L2 Polyclonal Antibody (Product # PA5-64172) shows low expression as expected.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 Detection of SEZ6L2-ab using a HEK293 cell-based assay HEK293 cells were transfected to express SEZ6L2 and incubated live, not permeabilized, with a patient's (A-C) or control (D-F) serum. Patient's serum, but not control serum, stained the cell surface of cells (green) that specifically express SEZ6L2, as demonstrated by the Myc-tag antibody (red). Both reactivities are shown merged in C. Nuclei counterstained with 4',6-diamidino-2-phenylindole (DAPI). Scale bar = 10 mum. (G, upper row): Western blot showing that the 4 patients' serum samples with SEZ6L2-ab (lanes 2-5) immunoprecipitated SEZ6L2. Lane 1 shows the immunoprecipitation using the commercial antibody, and lanes 6-9 demonstrate the lack of SEZ6L2 immunoprecipitation with 6 control samples. (G, lower row): Immunoblot strips of cell lysates of SEZ6L2-expressing HEK293 cells under denaturing conditions. None of the patient's serum (lanes 2-5) reacted with the denaturalized SEZ6L2 protein. Strips were also tested with a commercial SEZ6L2-ab (lane 1) and 6 control human sera (lanes 6-11). (H-K) Example of detection of SEZ6L2-ab IgG subclasses using a HEK293 cell-based assay. This patient's serum had IgG1 and IgG4 SEZ6L2-ab (green reactivity) being the IgG1 subclass immunoreactivity (H) more intense than that of the IgG4 (K). Nuclei counterstained with DAPI. IgG = immunoglobulin G.